All News Dimerix Limited

Equities

DXB

AU000000DXB7

Market Closed - Australian S.E. Other stock markets 02:10:13 2024-06-06 am EDT			5-day change	1st Jan Change
0.54 ^AUD	+10.20%		+35.00%	+163.41%

May. 29	Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy	MT
May. 27	Dimerix Signs License Deal for Kidney Disease Medication in the Middle East	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy	May. 29	MT
Dimerix Signs License Deal for Kidney Disease Medication in the Middle East	May. 27	MT
Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	Apr. 30	MT
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	Apr. 22	MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target	Apr. 19	MT
Dimerix Raises AU$20 Million for Kidney Disease Study	Mar. 12	MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	Mar. 10	MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Dimerix Limited Announces Appointment of Mark Diamond as Director	Nov. 30	CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	Nov. 27	MT
Dimerix Appoints Nonexecutive Chair	Nov. 19	MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	Nov. 07	MT
Dimerix Appoints Medical Chief	23-10-22	MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	23-10-22	CI
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	23-10-05	AQ
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	23-10-05	MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	23-10-05	MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	23-09-25	MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	23-09-22	MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	23-09-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Dimerix Limited

Equities

DXB

AU000000DXB7

All News

Filters